With the recent development of the ongoing Covid-19 pandemic, there has been increased urgency for industry and non-industry sponsors to concentrate on discovering a suitable therapeutic or vaccine for this highly contagious viral disease. Therefore, more Covid-19 clinical trials are being prepared and launched, while a vast number of clinical trials for non-Covid-19 indications are experiencing setbacks.
High profile pharmaceutical companies have declared interruptions to intended and continuing trials, delaying trial start dates and pausing subject enrolment. Read more here.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
